Catalyst Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update GlobeNewswire November 05, 2025 Reported Q3 2025 Total Revenues of $148.4 Million, Driven by Continued FIRDAPSE(R) Growth, Strong AGAMREE(R) Uptake and Growth, and Continued Demand for FYCOMPA(R) Raising Full-Year 2025 Total Revenue Guidance to between $565 Million and $585 Million, Reflecting Better than […]

Lucid Group, Inc. (NASDAQ: LCID), maker of the world's most advanced electric vehicles, today announced key organizational changes designed to accelerate growth, streamline decision-making, and enhance accountability as the company scales globally. https://mma.prnewswire.com/media/1080273/LucidMotors_Logo.jpg To support these objectives, Lucid has made the following organizational changes: — Emad Dlala has been appointed Senior Vice President, Engineering and

— Revenue, Adjusted EBITDA1 and Adjusted Free Cash Flow1 once again all ahead of expectations — Adjusted EBITDA margin1 of 31.6%, highest in Company's history and 90 basis points increase over the prior year period2 — 7.3% organic price and volume growth with pricing accelerating sequentially by 50 basis points to6.3% — Fourth consecutive quarter

Financial Highlights — Produced 3,891 vehicles in Q3, up 116% compared to Q3 2024, with more than 1,000 additional vehicles built for Saudi Arabia for final assembly — Delivered 4,078 vehicles in Q3; up 47% compared to Q3 2024 — Q3 revenue of $336.6 million; up 68% compared to Q3 2024 — Subsequent to quarter

Accuray Incorporated (NASDAQ: ARAY) today reported financial results for the first quarter ended September 30, 2025. https://mma.prnewswire.com/media/320376/accuray_incorporated_logo.jpg Key Highlights — On October 20, 2025, the Company announced accelerated transformation efforts, including: — Appointed Steve LaNeve as President and Chief Executive Officer. He succeeds Suzanne Winter, who will retire after six years of service and remain

Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, today reported financial results for the third quarter ended September 30, 2025. https://mma.prnewswire.com/media/2652215/Penumbra_Inc_Logo.jpg — Revenue of $354.7 million in the third quarter of 2025, an increase of 17.8% or 16.9% in constant currency1, compared to the third quarter of 2024. — Total U.S. revenue of $275.0

Talphera, Inc. (Nasdaq: TLPH), (“Talphera”), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that it will release third quarter 2025 financial results after market close on Wednesday, November 12, 2025, then host a live webcast and conference call at 4:30 p.m. Eastern

Modeyso™ approved as the first and only treatment for recurrent H3 K27M-mutant DMG – Zepzelca® and atezolizumab (Tecentriq®) combination approved as maintenance therapyin 1L ES-SCLC – 3Q25 total revenues increased 7% year-over-year driven by robust growth ofEpidiolex®, Xywav® and the launch of Modeyso – Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the

Miami International Holdings, Inc. (MIAX) (NYSE: MIAX), a technology-driven leader in building and operating regulated financial markets across multiple asset classes, today reported October 2025 trading results for its U.S. exchange subsidiaries – MIAX®, MIAX Pearl®, MIAX Emerald® and MIAX Sapphire® (collectively, the MIAX Exchange Group), and MIAX Futures™. https://mma.prnewswire.com/media/2635716/MIAX_new_Logo.jpg October 2025 and Year-to-Date Highlights

Hamilton Beach Brands Holding Company (NYSE: HBB) (The Company) today announced results for the third quarter of 2025. ThirdQuarter 2025 Overview — Revenue declined 15.2% to $132.8 million compared to $156.7 million — Gross margin decreased to 21.1% compared to 28.0%; 3Q25 gross margin included a one-time 370 basis point impact mostly from the flow